Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Since then, over 3,500 healthcare professionals have prescribed Ohtuvayre, and more than 16,000 prescriptions have been filled. About one-third of those prescriptions were patient refills ...

The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...

The company’s Q4 pre-announcement was “impressive”, with Ohtuvayre revenue outlook reflecting the firm’s view that getting patients on Medicare Part B drugs is much easier than getting ...